UPDATE : Tuesday, April 7, 2020
상단여백
Genome to conduct immunotherapy combo trial with Merck, Pfizer
Genome & Company, a local clinical-stage biotechnology business, said that ...
by Lee Han-soo  |  2020-01-16 14:47
라인
GSK to target ovarian cancer, multiple myeloma, endometrial cancer
After entering the oncology market with the acquisition of Tesaro in late 2...
by Kim Yun-mi  |  2020-01-16 14:10
라인
Sweden prolongs financial support for IVI’s vaccine development
The International Vaccine Institute (IVI) said that the Swedish Internation...
by Lee Han-soo  |  2020-01-16 10:45
라인
Pharmaceutical association lays out plans for 2020
The Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) l...
by Lee Han-soo  |  2020-01-15 14:29
라인
AptaBio attending J.P. Morgan event for global collaboration
AptaBio, a maker of drugs to treat cancer and diabetic complications, said ...
by Shim Hyun-tai  |  2020-01-15 13:06
라인
GC Pharma's US offshoot opens new plasma center
GC Pharma said Green Cross America (GCAM), its U.S. branch to secure plasma...
by Shim Hyun-tai  |  2020-01-15 13:05
라인
Jeil, Oncocross to discover new indications for stroke therapy
Jeil Pharmaceutical said that it will partner with Oncocross, a local ventu...
by Lee Han-soo  |  2020-01-15 11:31
라인
Will Steglatro prove SGLT-2 inhibitor’s cardiovascular benefits?
MSD is expected to announce the results of a study, whether Steglatro (ingr...
by Kim Yun-mi  |  2020-01-14 15:28
라인
Genexine becomes largest shareholder of GenNBio
GenNBio said that Genexine has become its largest shareholder. The announce...
by Lee Han-soo  |  2020-01-14 11:11
라인
Daewoong, A2A to develop AI-based anticancer treatment
Daewoong Pharmaceutical said that it would develop an anticancer treatment ...
by Lee Han-soo  |  2020-01-14 10:35
라인
GSK shows meaningful response rate for treatment of multiple myeloma
GSK Korea said that treatment with the investigational single-agent belanta...
by Lee Han-soo  |  2020-01-13 17:48
라인
Zejula widens indication as monotherapy for ovarian cancer
Takeda’s PARP (poly ADP-ribose polymerase) inhibitor Zejula (ingredient: ni...
by Kim Yun-mi  |  2020-01-13 16:25
라인
Vivozon positive of Opiranserin’s efficacy despite failures to meet primary endpoint
Vivozon said that it has started on a design change for its phase 3b clinic...
by Lee Han-soo  |  2020-01-13 16:22
라인
Lilly secures atopic dermatitis drug through Dermira acquisition
Lilly has enhanced its immune disease pipelines by obtaining the rights to ...
by Kim Yun-mi  |  2020-01-13 14:05
라인
Latecomer Bavencio improves overall survival in bladder cancer trial
Bavencio (ingredient: avelumab), a latecomer in the Tecentriq-led immune ch...
by Kim Yun-mi  |  2020-01-10 14:23
라인
HLB gets UAE’s nod for joint company with local partner
Elevar therapeutics, a U.S. subsidiary of HLB, said that the United Arab Em...
by Lee Han-soo  |  2020-01-08 16:31
라인
Daewoong, Avacta to establish joint venture
Daewoong Pharmaceutical said that it plans to set up a joint venture (JV) w...
by Lee Han-soo  |  2020-01-08 12:25
라인
Genexine licenses out immunosuppressant candidate to GenNBio
Genexine said that it has licensed out BSF-110, a dual-fusion immunosuppres...
by Lee Han-soo  |  2020-01-07 17:35
라인
Mundipharma to market Biosolution's knee cartilage defect treatment
Biosolution said that it has signed an exclusive sales agreement with Mundi...
by Lee Han-soo  |  2020-01-07 16:11
라인
Fenbendazole craze expands to human parasiticide
Following the craze over fenbendazole, a dog deworming drug, in treating ca...
by Lee Han-soo  |  2020-01-07 12:33
여백
여백
여백
여백
Back to Top